about
Virus entry as a target for anti-HIV interventionAnti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infectionAntiretroviral agents effectively block HIV replication after cell-to-cell transfer.Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors.A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 proteaseSAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitorsZinc finger endonuclease targeting PSIP1 inhibits HIV-1 integration.Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope.ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.Applications of 3-aminolactams: design, synthesis, and biological evaluation of a library of potential dimerisation inhibitors of HIV1-protease.Characterization of the influence of mediator complex in HIV-1 transcription.Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.HIV entry inhibitors.Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells.Sch-351125 and Sch-350634. Schering-Plough.Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents.Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.HIV-resistance to viral entry inhibitors.Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors.The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells.Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophagesTrans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cellsApoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: role of mitochondria and caspases.Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents.The cortical actin determines different susceptibility of naïve and memory CD4+ T cells to HIV-1 cell-to-cell transmission and infection.Polymorphic LEDGF/p75 variants support efficient HIV-1 infection ex vivo.Insights from host genomics into HIV infection and disease: Identification of host targets for drug development.Highlights of the 30th International Conference on Antiviral Research.RNA interference as a tool for target validation.SAMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction.Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors.Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
P50
Q28188138-A54E6E6D-F203-4FAA-8D3E-80F9673DE479Q28378177-9B88152D-5998-4057-9267-751D8E065A19Q30524224-AB8D3883-BC7B-4BDB-B937-88F3EE8B479EQ31138625-A137B576-9677-4E2D-8FF9-B09B41FC479CQ33356674-6B02E26E-3FA5-44B0-8FDE-17B57482FE42Q33979321-491109B6-C76C-4E19-A42F-AF16DBCF151AQ34058270-76C8B520-C198-4989-AA60-DB475C72A6BBQ34058383-3A6A1BEF-BFD3-4502-8FE7-0BDD8A7E98A6Q34077065-E5E9EF25-8D38-49E2-9BA7-B58F800289A7Q34090039-3632B3D6-41A7-4DB6-913C-787EDFF4BD7FQ34151017-C05303CF-6B6D-4074-8412-D6017C6FC7E9Q34185049-11B5CF70-4414-477C-A2CE-62F31A7613C7Q34227464-019FC536-DC09-4E40-B01E-F1004015260BQ34252258-AD371AFA-A675-47D2-8A47-16C8338AAE0FQ34283463-170CF00F-E48B-4026-809B-250D82E7D627Q34288166-F5DF5E3A-3EEF-4CE3-84E2-594552CA359CQ34654433-A751CDD9-AFEF-4D4E-9893-B62B338C0461Q34663141-D39A9E22-09AC-4D9E-90B4-07C91A0C65DCQ34675599-7E947DC3-086C-45B9-B28D-8F62335EA928Q34787546-829B40A1-E72D-4865-8F90-99DFB3FAFE95Q35182388-4DE483C4-DA07-44B1-9504-1AC7A2627168Q35794143-E94A3347-8CD7-4F9B-B6A1-F428D7680253Q35982151-6693CB73-4248-42B1-9523-69F722B7D41EQ36107799-28E5D8AD-6BD0-4044-9FC7-A75191170574Q36186478-B558D52A-45AE-46BB-809F-C2671908C264Q36234765-80FEE555-8B55-4AAA-8641-32E8AD9FA6DDQ36376051-67DADFA3-D436-4612-8758-65DD1B1E3182Q36904981-BA0D8540-AED4-4ABB-BFCD-529CEFD0152EQ37296695-20A43BE7-064A-4A9B-B5F7-B72F7208BD42Q37375759-911CB479-FE3B-45EB-8A6B-8C260D2B7200Q38148370-6A02B501-F867-4210-B209-73440A579430Q38157080-20A6E72F-D3CC-4020-9442-85BD09C58CBCQ38224986-D3010667-53D6-4373-91CC-407310406F9AQ38599942-BB51E747-7D7E-481E-ACA3-68F33D8D1E2FQ38809938-78DC01AF-3561-4202-8147-F475D00C5C56Q38887224-79C2ECEC-535F-4D52-99BB-4E600CE5B0D9Q38984313-ECF08233-C065-4571-86CA-F3B9CEE948DCQ39000998-05C30D46-24F3-4930-BA3C-38064FD7BCA0Q39002835-FB3ABA39-6F6C-4C73-9711-62A42DDBA144Q39328586-334FAFA5-AF12-42E8-9994-C7CD6AEE0AB0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
José A. Esté
@ast
José A. Esté
@en
José A. Esté
@es
José A. Esté
@nl
José A. Esté
@sl
type
label
José A. Esté
@ast
José A. Esté
@en
José A. Esté
@es
José A. Esté
@nl
José A. Esté
@sl
altLabel
JAE
@en
Jose A. Este
@en
José Esté
@en
prefLabel
José A. Esté
@ast
José A. Esté
@en
José A. Esté
@es
José A. Esté
@nl
José A. Esté
@sl
P1053
B-5509-2008
P106
P1153
7006560346
P21
P31
P3829
P496
0000-0002-1436-5823